Drug intelligence / Profile preview

Simbadol

Development stage: Unknown
Lead developer: Zoetis
Modality: Small Molecules
Administration: Subcutaneous

Overview

**Simbadol** is a veterinary brand name for a high-concentration buprenorphine injection (1.8 mg/mL) specifically formulated for subcutaneous administration in cats, providing 24-hour postoperative pain control with a single dose of 0.24 mg/kg. As a partial opioid agonist, it binds with high affinity to μ-opiate receptors in the central nervous system, delivering potent, long-acting analgesia due to slow receptor dissociation. Developed and manufactured by Zoetis, it is FDA-approved exclusively for cats undergoing surgical procedures and is a Schedule III controlled substance.[1][2][4][7][8]

Brand names: Simbadol

Targets

KOR (Kappa opioid receptor)DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on Simbadol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Simbadol.

Explore the full profile